Aclarion (ACON) EBITDA Yield: History & Chart

Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.

The EBITDA yield is N/A as of 2026-10-06T13:25:15.415Z.

Stored calculation inputs

Calculation as of: 2026-10-06T13:25:15.415Z.

Quote observation: 2026-10-05T20:00:02.000Z. Amounts in USD. The price header may show a later quote.

TTM operating EBITDA · period ending 2026-06-30: -9,468,166
Quote market capitalization: 6,744,748
Total debt · period ending 2026-06-30: 0
Cash · period ending 2026-06-30: 16,285,462

FMP input reference: 1aa4897ea94b4447735fa2b7e4a8bb5a18d1bcefabda34b81af7232f4abbcb6a

EV/EBITDA|Earnings Yield|OCF Yield|FCF Yield|All Metrics

ACON EBITDA Yield Metrics

EBITDA YIELD

N/A

ACON Competitors' EBITDA Yield

ACON

Aclarion, Inc.

Current

Market Cap

$6.74M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ENVB

Enveric Biosciences, Inc.

vs ACON

Market Cap

$6.76M

EBITDA Yield

N/A

TTM Avg

3.10%

3Y Avg

3.10%

5Y Avg

1.95%

BOLT

Bolt Biotherapeutics, Inc.

vs ACON

Market Cap

$6.72M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CODX

Co-Diagnostics, Inc.

vs ACON

Market Cap

$6.88M

EBITDA Yield

N/A

TTM Avg

372.43%

3Y Avg

151.61%

5Y Avg

151.61%

KALA

KALA BIO, Inc.

vs ACON

Market Cap

$7.01M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CURX

Curanex Pharmaceuticals Inc Common Stock

vs ACON

Market Cap

$7.03M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ENSC

Ensysce Biosciences, Inc.

vs ACON

Market Cap

$6.44M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

BMRA

Biomerica, Inc.

vs ACON

Market Cap

$6.34M

EBITDA Yield

N/A

TTM Avg

1.29%

3Y Avg

1.35%

5Y Avg

1.32%

INM

InMed Pharmaceuticals Inc.

vs ACON

Market Cap

$7.31M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

FEMY

Femasys Inc.

vs ACON

Market Cap

$6.10M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EBITDA YIELD	TTM	3Y	5Y
Aclarion, Inc. (ACON)	$6.74M	N/A	N/A	N/A	N/A
Enveric Biosciences, Inc. (ENVB)vs ›	$6.76M	N/A	3.10%	3.10%	1.95%
Bolt Biotherapeutics, Inc. (BOLT)vs ›	$6.72M	N/A	N/A	N/A	N/A
Co-Diagnostics, Inc. (CODX)vs ›	$6.88M	N/A	372.43%	151.61%	151.61%
KALA BIO, Inc. (KALA)vs ›	$7.01M	N/A	N/A	N/A	N/A
Curanex Pharmaceuticals Inc Common Stock (CURX)vs ›	$7.03M	N/A	N/A	N/A	N/A
Ensysce Biosciences, Inc. (ENSC)vs ›	$6.44M	N/A	N/A	N/A	N/A
Biomerica, Inc. (BMRA)vs ›	$6.34M	N/A	1.29%	1.35%	1.32%
InMed Pharmaceuticals Inc. (INM)vs ›	$7.31M	N/A	N/A	N/A	N/A
Femasys Inc. (FEMY)vs ›	$6.10M	N/A	N/A	N/A	N/A

EBITDA Yield Formula & Definition

EBITDA Yield = TTM EBITDA / Enterprise Value

EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

EBITDA Yield: N/A

ACON EBITDA Yield Metrics

ACON Competitors' EBITDA Yield

EBITDA Yield Formula & Definition

Related Metrics